The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice

To study the impact of dose modification and temporary interruption of ibrutinib in routine clinical practice, we conducted a retrospective study of consecutive CLL patients treated with ibrutinib outside the context of a clinical trial at Mayo Clinic, (Rochester, MN) from 11/2013 to 12/2017. Of 209...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Med
Autors principals: Parikh, Sameer A., Achenbach, Sara J., Call, Timothy G., Rabe, Kari G., Ding, Wei, Leis, Jose F., Kenderian, Saad S., Chanan‐Khan, Asher A., Koehler, Amber B., Schwager, Susan M., Muchtar, Eli, Fonder, Amie L., McCullough, Kristen B., Nedved, Adrienne N., Smith, Matthew D., Slager, Susan L., Kay, Neil E., Finnes, Heidi D., Shanafelt, Tait D.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2020
Matèries:
Clinical Cancer Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7221301/
https://ncbi.nlm.nih.gov/pubmed/32187452
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.2998
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars